ARGX Quote, Financials, Valuation and Earnings

Autolus Therapeutics Plc has a net margin of 25.88% compared to argenx SE's net margin of -373.3%. argenx SE's return on equity of 28.06% beat Autolus Therapeutics Plc's return on equity of -59.51%.

argenx SE has a consensus price target of $1,031.68, signalling upside risk potential of 33.72%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $8.99 which suggests that it could grow by 407.91%. Given that Autolus Therapeutics Plc has higher upside potential than argenx SE, analysts believe Autolus Therapeutics Plc is more attractive than argenx SE.

argenx SE has a beta of 0.374, which suggesting that the stock is 62.596% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.946%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than Autolus Therapeutics Plc quarterly revenues of $21.1M. argenx SE's net income of $245.4M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, argenx SE's price-to-earnings ratio is 42.59x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 16.45x versus 9.19x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 25.88% compared to argenx SE's net margin of --. argenx SE's return on equity of 28.06% beat DBV Technologies SA's return on equity of -280.59%.

argenx SE has a consensus price target of $1,031.68, signalling upside risk potential of 33.72%. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 86.61%. Given that DBV Technologies SA has higher upside potential than argenx SE, analysts believe DBV Technologies SA is more attractive than argenx SE.

argenx SE has a beta of 0.374, which suggesting that the stock is 62.596% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than DBV Technologies SA quarterly revenues of --. argenx SE's net income of $245.4M is higher than DBV Technologies SA's net income of -$33M. Notably, argenx SE's price-to-earnings ratio is 42.59x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 16.45x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Mereo BioPharma Group Plc has a net margin of 25.88% compared to argenx SE's net margin of -2923.31%. argenx SE's return on equity of 28.06% beat Mereo BioPharma Group Plc's return on equity of -70.81%.

argenx SE has a consensus price target of $1,031.68, signalling upside risk potential of 33.72%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $2.65 which suggests that it could grow by 586.36%. Given that Mereo BioPharma Group Plc has higher upside potential than argenx SE, analysts believe Mereo BioPharma Group Plc is more attractive than argenx SE.

argenx SE has a beta of 0.374, which suggesting that the stock is 62.596% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.310, suggesting its less volatile than the S&P 500 by 68.983%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. argenx SE's net income of $245.4M is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, argenx SE's price-to-earnings ratio is 42.59x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 16.45x versus 120.46x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.

Koninklijke Philips NV has a net margin of 25.88% compared to argenx SE's net margin of 7.71%. argenx SE's return on equity of 28.06% beat Koninklijke Philips NV's return on equity of 7.99%.

argenx SE has a consensus price target of $1,031.68, signalling upside risk potential of 33.72%. On the other hand Koninklijke Philips NV has an analysts' consensus of $35.15 which suggests that it could grow by 9.57%. Given that argenx SE has higher upside potential than Koninklijke Philips NV, analysts believe argenx SE is more attractive than Koninklijke Philips NV.

argenx SE has a beta of 0.374, which suggesting that the stock is 62.596% less volatile than S&P 500. In comparison Koninklijke Philips NV has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.659%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Koninklijke Philips NV offers a yield of 3.02% to investors and pays a quarterly dividend of $0.97 per share. argenx SE pays -- of its earnings as a dividend. Koninklijke Philips NV pays out 94.78% of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

argenx SE quarterly revenues are $948M, which are smaller than Koninklijke Philips NV quarterly revenues of $5.9B. argenx SE's net income of $245.4M is lower than Koninklijke Philips NV's net income of $457.4M. Notably, argenx SE's price-to-earnings ratio is 42.59x while Koninklijke Philips NV's PE ratio is 30.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 16.45x versus 1.52x for Koninklijke Philips NV. Usually stocks with elevated PS ratios are considered overvalued.